Bioceres Crop Solutions Corp. Q4 FY2026 earnings call

• Financial Turnaround via Cost Actions: The company successfully returned to positive adjusted EBITDA in Q4 ($0.6 million) after years of losses, driven by a material reduction in the expense base. SG&A expenses decreased by 19% in Q4, offsetting declines in gross profit.
• Portfolio Rationalization: Bioceres substantially completed a two-year reconfiguration of its seed business and concluded an external strategic assessment. The focus is now on rationalizing the product portfolio, simplifying go-to-market channels, and aligning R&D investments with financial objectives.
• Profitability Improvement Underlying Metrics: Excluding non-recurring inventory obsolescence adjustments (approx. $4 million in Q4), gross profit percent expanded from FY25 to FY26. The underlying portfolio composition is improving, with greater concentration in higher-margin products.
• Strategic Focus on Core Strengths: Management is shifting focus toward higher-quality core revenue streams, particularly in Brazil, and concentrating on the most value-accretive SKUs. Notably, 99% of aggregated gross profit in FY25 came from less than 50% of the SKUs in the catalog.
• Operational Stability in Argentina: Commercial operations in Argentina have stabilized following the successful reprofiling of local debt obligations in Q4, helping to mitigate some of the challenges faced during the fiscal year.

• Crop Nutrition: Revenues were broadly stable for the full year. In Q4, this segment grew by 36% year-over-year, driven primarily by strong performance in microbially-created fertilizer (microbeated fertilizer). Gross profit for this segment increased by 37% in Q4 due to high revenues and improved margins.
• Crop Protection: Full-year revenues declined, contributing significantly to the overall revenue drop. However, gross margins remained broadly stable despite lower revenues. In Q4, third-party and other products saw declines, but the adjuvant portfolio delivered higher gross profit and improved margins year-over-year.
• Seeds and Integrated Products: Approximately half of the full-year revenue decline was associated with the reconfiguration of the seed business strategy. While remaining seeds continued to weigh on reported results, seed treatment packs delivered higher sales and approximately 40% growth in gross profit.

• Gross Margin Target: For FY27 and beyond, management targets approximately 40% gross margins. This goal relies on focusing growth on higher-quality core revenue streams and simplifying the product portfolio to focus on high-value SKUs.
• SG&A Efficiency Target: Management aims to achieve a combined total SG&A ratio of 23% as a percent of revenues by fiscal year 28. This target assumes continued implementation of new systems, simplified organizational structures, and process efficiencies.
• Cost Structure Discipline: The company emphasizes maintaining cost and working capital discipline as it enters FY27, leveraging the more linear operating structure established through recent cost resets.

• Ongoing Litigation and Debt Dispute: The company faces ongoing litigation with certain creditors in New York regarding the acceleration of notes and foreclosure processes. Substantially all related secured notes ($118.6 million at year-end) remain classified as short-term, creating significant liquidity and balance sheet uncertainty.
• Liquidity Constraints: Total financial debt stands at $225.9 million, with cash and short-term investments totaling only $12.2 million, resulting in net financial debt of $213.6 million. Managing liquidity and the capital structure remains a key priority amidst the legal disputes.
• Inventory Obsolescence: The quarter included significant non-recurring inventory adjustments related to obsolescence following a comprehensive review, which impacted reported gross profit and highlighted risks associated with legacy or slow-moving inventory.

No questions were asked during the session; the operator reported no takers before returning the call to management for closing remarks.